JLJoan-Ramon Laporte

Joan-Ramon Laporte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joan-Ramon Laporte has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vaccines against Covid-19, venous thromboembolism, and thrombocytopenia. A population-based retrospective cohort study

    by Joan-Ramon Laporte, Ermengol Coma, Francesc Fina, Luís García-Eroles, Xavier Vidal, Manuel Medina

    Background Covid-19 vaccines may increase the risk of venous thromboembolism (VTE), thrombocytopenia (TCP), and VTE associated with TCP. We aimed at estimating this risk by age and sex, after the first dose of both adenovirus vector-based and mRNA-based Covid-19 vaccines, and after the second dose of m-RNA vaccines. Methods In this population-based retrospective cohort study, we examined three groups: 1 662 719 people 10 years of age and over vaccinated with the first dose of a Covid-19 vaccine, 622 778 with the second dose, and 190 616 diagnosed of Covid-19 in the same period (between1 January 2021 and 18 April 2021). The rates of various clinical presentations of VTE and TCP were compared with those in the reference population (7 013 040 people served by the health care system in 2919). The two primary outcomes were the observed 21 day rate of a composite variable of cerebral venous sinus thrombosis, mesenteric thrombosis, portal vein thrombosis, or any venous thromboembolism (VTE) associated with thrombocytopenia (TCP), and the rate of any VTE associated with TCP (VTE+TCP). Analyses were standardised by age and sex. Findings The 21 day rate per 100 000 of the primary composite variable was 2·15 in the reference population, 5·65 following the first vaccine dose (standardised difference, 2·53 (95 percent confidence interval, 1·04– 4·00), and 7·23 following the second dose (standardised difference, 4·07 (95 percent confidence interval, 1·43–6·70). The event rates of VTE+TCP and of all the secondary variables showed the same patterns. Excess event rates were higher in men than in women, and they were not especially increased in any particular age group. All Covid-19 vaccines were associated with increased rates of the outcome variables. Excess event rates were many-fold higher in the Covid-19 cohort. Interpretation We observed small increases of rates of venous thromboembolism in usual and unusual anatomical sites and of thrombocytopenia in recipients of both adenovirus vector and mRNA vaccines against Covid-19. Excess rates were higher in men than in women and they were not particularly elevated in any specific age group. Evidence before this study Covid-19 increases the risk of venous thromboembolism (VTE) in common and in unusual anatomical sites, and the risk of thrombocytopenia (TCP). This risk increases with age. Case reports of VTE and TCP after Covid-19 vaccination with VaxZevria®, an adenovirus vector Covid-19 vaccine, suggested that the risk concentrates in young women. One study based on systematic ascertainment found 11 excess VTE events per 100 000 first doses, but people over 65 years were excluded. It is not known whether mRNA-based Covid-19 vaccines are associated with increased risks of VTE and TCP. What this study adds Recipients of Covid-19 vaccines had increased rates of VTE in usual and in unusual anatomical sites, of TCP, and of VTE associated with TCP. These rates were many-fold lower than those in Covid-19 patients, they were two fold in men compared with women, and they were not concentrated in any particular age group. Both recipients of adenovirus vector-based and of mRNA-based Covid-19 vaccines had increased rates of VTE, TCP, and VTE associated with TCP, after the first dose and after the second dose. Our data should be considered when designing selective targeting of the various Covid-19 vaccines to different age groups in vaccination campaigns.


  • Open Access

    Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database

    by Leticia Ortiz de Landaluce, Pere Carbonell, Carmen Asensio, Núria Escoda, Pilar López, Joan-Ramon Laporte

    Gabapentin and pregabalin are widely prescribed to elderly people, but data on their pharmacokinetics, safety, and efficacy in this population are scarce. Neurological adverse effects are common. Atrial fibrillation (AF) associated with their use has been described in several case reports and case series, but the incidence is unknown.


  • Prevalence of use of antipsychotic drugs in the elderly in Catalonia

    by Carmen Asensio, Núria Escoda, Mònica Sabaté, Pere Carbonell, Pilar López, Joan-Ramon Laporte

  • Open Access

    Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010

    by Pili Ferrer, Mònica Sabaté, Elena Ballarín, Joan Fortuny, Marietta Rottenkolber, Sven Schmiedl, Joan-Ramon Laporte, Luisa Ibáñez

    Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.


  • Open Access

    A compilation of research working groups on drug utilisation across Europe

    by Mònica Sabaté, Juan Fernando Pacheco, Elena Ballarín, Pili Ferrer, Hans Petri, Joerg Hasford, Marieke Wilma Schoonen, Marietta Rottenkolber, Joan Fortuny, Joan-Ramon Laporte, et al.

    The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns of utilization. Systems for the monitoring of medicines consumption have been established in many European countries, and several international groups have identified and described them. No other compilation of European working groups has been published.


  • Crisis y política de medicamentos

    by Joan-Ramon Laporte, Montserrat Bosch


  • Open Access

    Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series

    by Mònica Sabaté, Luisa Ibáñez, Eulàlia Pérez, Xavier Vidal, Maria Buti, Xavier Xiol, Antoni Mas, Carlos Guarner, Montserrat Forné, Ricard Solà, et al.

    Background: Acute liver injury (ALI) induced by paracetamol overdose is a well known cause of emergency hospital admission and death. However, there is debate regarding the risk of ALI after therapeutic dosages of the drug. The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case. Methods: Based on the evaluation of prospectively gathered cases of ALI with detailed clinical information, thirty-two cases of ALI in non-alcoholic patients exposed to therapeutic doses of paracetamol were identified. Two authors assessed all drug exposures by using the CIOMS/RUCAM scale. Each case was classified into one of five categories based on the causality score for paracetamol. Results: In four cases the role of paracetamol was judged to be unrelated, in two unlikely, and these were excluded from evaluation. In seven of the remaining 26 cases, the RUCAM score associated with paracetamol was higher than that associated with other concomitant medications. The estimated incidence of ALI related to the use of paracetamol in therapeutic dosages was 0.4 per million inhabitants older than 15 years of age and per year (99%CI, 0.2-0.8) and of 10 per million paracetamol users-year (95% CI 4.3-19.4). Conclusions: Our results indicate that paracetamol in therapeutic dosages may be considered in the causality assessment in non-alcoholic patients with liver injury, even if the estimated incidence of ALI related to paracetamol appears to be low.


  • Open Access

    Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review

    by Eva Montané, Antoni Vallano, Xavier Vidal, Cristina Aguilera, Joan-Ramon Laporte

    Several randomised clinical trials (RCTs) of analgesics in postoperative pain after traumatic or orthopaedic surgery (TOS) have been published, but no studies have assessed the quality of these reports. We aimed to examine the quality of reporting RCTs on analgesics for postoperative pain after TOS.